Catalyst

Slingshot members are tracking this event:

Alecensa (alectinib) Phase 3 ALEX Study Results Expected mid-2017 - Roche Seeking Approval in Japan

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
RHHBY

100%

Additional Information

Additional Relevant Details The results of a Phase 3 ALEX study of Alecensa (alectinib) are expected in 2017 (study projected to complete March).  Alecensa was recently approved in the US and Roche is currently seeking approval for the drug in Japan.  Results from this study as well as positive results from Phase 2 studies will be used for the regulatory filing.
http://seekingalpha....
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 10, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Alecensa, Alectinib, Alex Study, Phase 3 Study, Alk Positive Lung Cancer, Non-small Cell Lung Cancer